Business Wire

The Estée Lauder Companies Announces Brand Leadership Promotions

1.7.2021 15:30:00 EEST | Business Wire | Press release

Share

The Estée Lauder Companies (NYSE:EL) announced today the promotions of two brand leaders – Michelle Freyre has been promoted to Global Brand President, Clinique, and Glenn Evans has been promoted to Global Brand President, Smashbox and GLAMGLOW. The promotions are effective July 1, 2021, and both leaders will continue to report directly to John Demsey, Executive Group President, The Estée Lauder Companies (ELC).

“Michelle and Glenn are both incredibly dynamic leaders who have beautifully steered their respective brands through the challenges of the past year,” said John Demsey. “I am particularly proud of how effectively they have balanced the needs of the business while being truly thoughtful and empathetic leaders to their brand teams. Their promotions are both very well-deserved.”

Michelle Freyre Has Been Promoted to Global Brand President, Clinique

A dynamic leader with deep experience leading a variety of beauty brands across categories and channels, Michelle’s promotion to Global Brand President, Clinique, recognizes her outstanding and visionary leadership in returning Clinique to global growth. She was appointed Senior Vice President/Global General Manager, Clinique in June 2020, and since then has made a significant impact on Clinique’s brand positioning, driving double digit growth for hero products, as well as redefining the innovation strategy behind Clinique’s hero franchises. She has also driven Clinique’s acceleration in Online to be the #1 ELC brand in North America in that channel, while delivering the Clinique High-Touch experience at scale globally. Her inspirational leadership, deep expertise in beauty and skin care, together with her strong passion for connecting with global consumers, makes her uniquely suited to continue to lead Clinique in its next chapter of growth.

Michelle joined ELC from Johnson & Johnson in 2020, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of Beauty brands at the time, and led the successful performance and growth of many brands. Prior to that, she served as the General Manager of Neutrogena at J&J, and as the leader of the company’s Los Angeles campus.

Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity. She has received several industry awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.”Michelle is the Executive Sponsor of Hispanic Connections (HiC) ERG and is actively mentoring diverse talent across ELC.

Glenn Evans Has Been Promoted to Global Brand President, Smashbox and GLAMGLOW

With more than 30 years of strategic, operational and brand-building experience, Glenn is an exceptional, values-driven brand leader with an impressive track record of delivering consistent results. As Senior Vice President/Global General Manager, Smashbox and GLAMGLOW, Glenn has successfully led both brands, capturing operational and supply chain synergies between them, optimizing their global brand and regional go-to-market structures and improving A&P effectiveness.

As Global Brand President, Glenn will continue to lead Smashbox and GLAMGLOW into their next phases of sustainable growth, focusing on product innovations with a consumer-led, online-centric, digital-first approach, as well as continuous transformation to evolve ahead of the changing retail landscape. A dynamic and energetic leader, Glenn will also continue to leverage his passion for developing top talent across both brand teams.

Since being named Senior Vice President and General Manager, Smashbox, in 2019, Glenn has led the brand’s repositioning strategy to drive appeal with both new and loyal consumers while staying true to the brand’s core studio heritage. Under his leadership, the brand reinforced its number one ranking in U.S. prestige Face Primers, achieved top rankings in prestige Face Primers in key global markets, and attracted new consumers with the success of Smashbox Halo All-in-One Tinted Moisturizer.

Before his role at Smashbox, Glenn was Senior Vice President, Leading Beauty Forward, where he led the successful global implementation of Leading Beauty Forward and OneSource, which have helped to fuel the company’s multiple engines of growth strategy. Prior to that role, Glenn was SVP, Global Supply Chain, during which time he established and led the Global Supply Chain Center of Excellence for six years, and played a leadership role in integrating and enhancing best-in-class capabilities across the organization.

Since 2018, Glenn has served as an Executive Sponsor of wELCome, ELC’s Employee Resource Group for LGBTQIA+ employees. He continues to act as a passionate advocate for Inclusion & Diversity across the Company. Glenn recently announced the creation of the West Coast chapter of wELCcome and he also sponsors the Smashbox & GLAMGLOW Multi-Ethnic Advisory Board, an employee-led group within the brands that aims to ensure diverse voices are amplified during key moments of decision-making.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Rainey Mancini
(212) 284-3049
rmancini@estee.com

Media Relations:
Jill Marvin
(212) 572-4438
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye